Drugs / Recombinant Mycobacterium Tuberculosis Fusion Protein
Recombinant Mycobacterium Tuberculosis Fusion Protein
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05899179 | Aug 2023 → Jul 2025 | latent tuberculosis infection | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05746611 | Apr 2023 → May 2024 | latent tuberculosis infection | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Mycobacterium Tuberculosis Fusion Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05899179 ↗ |
| Modality | Protein / enzyme biologic | “recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 (EC)” PMID 40560769 ↗ Oct 2025 |
| Route | Other | “the product was injected intradermally into the volar side of the left forearm by the Mondu's method” NCT05746611 ↗ |